Ações terapêuticas do Metil-Eugenol na inflamação aguda de pulmão induzida em ratos

Abstract

Acute respiratory distress syndrome (ARDS) is an inflammatory disease that affects the lungs, with rupture of the alveolar-capillary barrier and loss of lung compliance orchestrated by an intense inflammatory process mediated by neutrophils that culminates in diffuse alveolar data and tissue hypoxia. In this context, no specific drug has yet been applied to treat the syndrome. Therefore, finding new therapeutic targets that can treat the syndrome has become a research study. In view of this, methyleugenol (ME) is the target of this study. The aim of this work was to carry out an in silico pharmacological and toxicological analysis with ADMET, as well as to determine the interaction affinity of the 5-lox and cox-2 enzymes with ME by means of molecular docking, and then in vivo tests; in which male rats were distributed into five groups with five rats each, in which some groups were subjected to the ischemia and reperfusion (I/R) process. Groups G4 and G5 were treated by inhalation with methyl-eugenol (10%). After completing these procedures, total cell counts and lung histology were performed. In the ADMET prediction, methyl-eugenol showed high intestinal absorption and a medium-permeability blood-brain barrier. Methyl-eugenol had no violations of Lipinski’s rule, demonstrating high potential as a drug candidate. Molecular docking showed that methyl-eugenol had the highest binding affinity with the enzyme.